Deals
Mubadala Eyes Bridgepoint’s $2.5 Billion Dialysis Firm Diaverum
- Sovereign investor among final bidders competing for business
- Abu Dhabi fund is keen to expand health care investments
This article is for subscribers only.
Sign up for our Middle East newsletter and follow us @middleeast for news on the region.
Mubadala Investment Co. is exploring an acquisition of Bridgepoint Group Plc’s European dialysis clinic chain Diaverum, in a deal that could value the business at about $2.5 billion, according to people familiar with the matter.